Peptides
Research-use compounds, mechanisms, and what the data actually supports.
The FDA's Peptide Compounding Fight: What the July 2026 PCAC Meeting Means for Gray Market Access and Pricing
BPC-157, KPV, TB-500, and MOTS-c go in front of the FDA's compounding advisory committee this month. Here's what's actually being decided, why it won't immediately change the gray market, and what's scheduled next.
Retatrutide: The Next GLP-1? What We Know So Far
Retatrutide has moved from Phase 2 buzz to real Phase 3 data in the last few months. Here's what the actual trial results show, and how they stack up against tirzepatide and semaglutide.
Melanotan I vs. Melanotan II: Same Origins, Very Different Safety Profiles
Both trace back to the same 1980s research program, but one became an FDA-approved orphan drug and the other stayed an unregulated tanning agent with a genuinely concerning real-world adverse event record. Here's how they actually differ.
RUO vs. Clinical Use: Understanding the Peptide Research Landscape
Research-use-only compounds occupy a specific, legal, and often misunderstood space in the peptide world. Here's what the label actually means — and what it doesn't.
What Is BPC-157? A Look at the Current Research
BPC-157 has over a hundred animal studies behind it and a passionate following online. Here's an honest look at what the animal data shows, how thin the human evidence actually is, and where the regulatory story stands right now.
Bacteriostatic Water vs. Bacteriostatic Saline: Which Is Actually Better for Reconstitution?
Both diluents share the same preservative doing the real work — but that preservative has a documented interaction with protein structure worth knowing about, and it changes how you should think about storage.
Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show
For years, tirzepatide vs. semaglutide was argued from separate trials in different populations. SURMOUNT-5 finally put them head-to-head in the same study. Here's what it actually found.
Semax vs. Dihexa: Similar Pitch, Very Different Evidence Base
Both get marketed as powerful nootropic peptides derived from natural hormone systems. One has real human clinical trial data behind it. The other's foundational research paper was retracted for fabricated data. Here's the actual comparison.
KPV for Inflammation and Gut Health: Why It May Be a More Targeted Research Tool Than BPC-157
KPV and BPC-157 both show up in gut and inflammation research, but they work through genuinely different mechanisms — and KPV's lack of angiogenic activity may make it the more precise tool for inflammation-specific research questions.
GHK-Cu: How This Copper Peptide Works, and the Surprising Range of Things It Does
GHK-Cu started as a curiosity found in human blood plasma and turned into one of the most broadly-studied peptides in skin, wound, and tissue research. Here's the mechanism, and the real range of documented effects.
KLOW: What's Actually in the Blend, and What the Research on Each Component Shows
KLOW combines four peptides into one vial for a reason — but the research behind each component is stronger than the research behind combining them. Here's what's actually known.